Comparison of effectiveness of Rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg/L) and low-density lipoprotein cholesterol (<70 mg/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study)
- Author
- BETTERIDGE, D. John1 2 ; GIBSON, J. Martin3 ; SAGER, Philip T4
[1] Department of Medicine, University College London, London, United Kingdom
[2] Department of Diabetes and Endocrinology, University College Hospital, London, United Kingdom
[3] Diabetes and Endocrinology, Hope Hospital, Salford, United Kingdom
[4] Cardiovascular Clinical Research, AstraZeneca, Wilmington, North Carolina, United States - Source
The American journal of cardiology. 2007, Vol 100, Num 8, pp 1245-1248, 4 p ; ref : 9 ref
- CODEN
- AJCDAG
- ISSN
- 0002-9149
- Scientific domain
- Cardiology, blood circulation, phlebology
- Publisher
- Elsevier, New York, NY
- Publication country
- United States
- Document type
- Article
- Language
- English
- Keyword (fr)
- Appareil circulatoire Atorvastatine Cardiologie Cholestérol Cible Diabète type 2 Efficacité Etude comparative Homme Hypercholestérolémie Lipide Lipoprotéine LDL Malade Phlébologie Protéine C réactive Rosuvastatine Dyslipémie Endocrinopathie Hyperlipoprotéinémie Métabolisme pathologie
- Keyword (en)
- Circulatory system Atorvastatin Cardiology Cholesterol Target Type 2 diabetes Efficiency Comparative study Human Hypercholesterolemia Lipids Lipoprotein LDL Patient Phlebology C reactive protein Rosuvastatin Dyslipemia Endocrinopathy Hyperlipoproteinemia Metabolic diseases
- Keyword (es)
- Aparato circulatorio Atorvastatina Cardiología Colesterol Blanco Diabetes de tipo 2 Eficacia Estudio comparativo Hombre Hipercolesterolemia Lípido Lipoproteína LDL Enfermo Flebología Proteína reactiva Rosuvastatina Dislipemia Endocrinopatía Hiperlipoproteinemia Metabolismo patología
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B12 Cardiology. Vascular system
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B21 Endocrinopathies / 002B21E Endocrine pancreas. Apud cells (diseases) / 002B21E01 Diabetes. Impaired glucose tolerance / 002B21E01A Etiopathogenesis. Screening. Investigations. Target tissue resistance
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B22 Metabolic diseases / 002B22A Disorders of blood lipids. Hyperlipoproteinemia
- Discipline
- Cardiology. Circulatory system Endocrinopathies Metabolic diseases
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 19174785
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1016/j.amjcard.2007.05.044 
https://dx.doi.org/10.1016/j.amjcard.2007.05.044
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/j.amjcard.2007.05.044\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:252:\"Comparison of effectiveness of Rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg\/L) and low-density lipoprotein cholesterol (<70 mg\/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study)\";s:9:\"\u0000*\u0000jtitle\";s:34:\"The American journal of cardiology\";s:9:\"\u0000*\u0000stitle\";s:14:\"Am. j. cardiol\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:3:\"100\";s:8:\"\u0000*\u0000issue\";s:1:\"8\";s:8:\"\u0000*\u0000spage\";s:4:\"1245\";s:8:\"\u0000*\u0000epage\";s:4:\"1248\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0002-9149\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"BETTERIDGE\";s:10:\"\u0000*\u0000aufirst\";s:7:\"D. John\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:17:\"GIBSON, J. Martin\";i:1;s:15:\"SAGER, Philip T\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"AJCDAG\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:252:\"Comparison of effectiveness of Rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg\/L) and low-density lipoprotein cholesterol (<70 mg\/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study)\";s:8:\"\u0000*\u0000place\";s:12:\"New York, NY\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"4\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/j.amjcard.2007.05.044\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:252:\"Comparison of effectiveness of Rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg\/L) and low-density lipoprotein cholesterol (<70 mg\/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study)\";s:9:\"\u0000*\u0000jtitle\";s:34:\"The American journal of cardiology\";s:9:\"\u0000*\u0000stitle\";s:14:\"Am. j. cardiol\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:3:\"100\";s:8:\"\u0000*\u0000issue\";s:1:\"8\";s:8:\"\u0000*\u0000spage\";s:4:\"1245\";s:8:\"\u0000*\u0000epage\";s:4:\"1248\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0002-9149\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"BETTERIDGE\";s:10:\"\u0000*\u0000aufirst\";s:7:\"D. John\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:17:\"GIBSON, J. Martin\";i:1;s:15:\"SAGER, Philip T\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"AJCDAG\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:252:\"Comparison of effectiveness of Rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg\/L) and low-density lipoprotein cholesterol (<70 mg\/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study)\";s:8:\"\u0000*\u0000place\";s:12:\"New York, NY\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"4\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/j.amjcard.2007.05.044\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/j.amjcard.2007.05.044\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:252:\"Comparison of effectiveness of Rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg\/L) and low-density lipoprotein cholesterol (<70 mg\/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study)\";s:9:\"\u0000*\u0000jtitle\";s:34:\"The American journal of cardiology\";s:9:\"\u0000*\u0000stitle\";s:14:\"Am. j. cardiol\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:3:\"100\";s:8:\"\u0000*\u0000issue\";s:1:\"8\";s:8:\"\u0000*\u0000spage\";s:4:\"1245\";s:8:\"\u0000*\u0000epage\";s:4:\"1248\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0002-9149\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"BETTERIDGE\";s:10:\"\u0000*\u0000aufirst\";s:7:\"D. John\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:17:\"GIBSON, J. Martin\";i:1;s:15:\"SAGER, Philip T\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"AJCDAG\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:252:\"Comparison of effectiveness of Rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg\/L) and low-density lipoprotein cholesterol (<70 mg\/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study)\";s:8:\"\u0000*\u0000place\";s:12:\"New York, NY\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"4\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:29:\"10.1016\/j.amjcard.2007.05.044\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:252:\"Comparison of effectiveness of Rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg\/L) and low-density lipoprotein cholesterol (<70 mg\/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study)\";s:9:\"\u0000*\u0000jtitle\";s:34:\"The American journal of cardiology\";s:9:\"\u0000*\u0000stitle\";s:14:\"Am. j. cardiol\";s:7:\"\u0000*\u0000date\";s:4:\"2007\";s:9:\"\u0000*\u0000volume\";s:3:\"100\";s:8:\"\u0000*\u0000issue\";s:1:\"8\";s:8:\"\u0000*\u0000spage\";s:4:\"1245\";s:8:\"\u0000*\u0000epage\";s:4:\"1248\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0002-9149\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:10:\"BETTERIDGE\";s:10:\"\u0000*\u0000aufirst\";s:7:\"D. John\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:17:\"GIBSON, J. Martin\";i:1;s:15:\"SAGER, Philip T\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"AJCDAG\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:252:\"Comparison of effectiveness of Rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg\/L) and low-density lipoprotein cholesterol (<70 mg\/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study)\";s:8:\"\u0000*\u0000place\";s:12:\"New York, NY\";s:6:\"\u0000*\u0000pub\";s:8:\"Elsevier\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"4\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
